Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, randomized, controlled, multicenter phase III study comparing 5FU/ FA [fluorouracil + folinic acid] plus irinotecan (FOLFIRI) plus cetuximab [Erbitux; Merck] versus 5FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer

Next Previous
Trial Profile

Open, randomized, controlled, multicenter phase III study comparing 5FU/ FA [fluorouracil + folinic acid] plus irinotecan (FOLFIRI) plus cetuximab [Erbitux; Merck] versus 5FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CRYSTAL
  • Sponsors Merck KGaA

    • Most Recent Events

    • 05 Oct 2021 Planned number of patients changed from 1080 to 1300.
    • 02 Mar 2017 According to a Merck KGaA media release, based on the data from this and other three studies (CTP: 15696, 37756 and 60760) the UK National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Erbitux (cetuximab) in combination with either FOLFIRI or FOLFOX as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).
    • 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top